COVID-19 Windfall Will Help Pfizer Remain Top Drug Company
Pfizer splits earnings on the vaccine evenly with BioNTech
Pfizer said it expects its COVID-19 vaccine to generate $15bn in 2021, but the forecast appears to be an underestimation as it includes only contracted doses.
You may also be interested in...
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Management said it remains confident in Xeljanz and believes next-generation JAKs will be sufficiently differentiated. Pfizer's Vyndaqel and biosimilars businesses emerged as new blockbusters.